Emtricitabin, tenofovir-alafenamid a biktegravir
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1145/2024-SML | 06. 06. 2024 | Gilead Sciences s.r.o. | 93 636 466,56 | 83 603 988,00 | 93 636 466,56 | 83 603 988,00 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| 01_Písemná zpráva zadavatele_Biktegravir_EP.pdf | Písemná zpráva zadavatele | 10. 06. 2024 09:35 | Dokument není zavirovaný |
List of Participants
| Show detail | ||||||
|---|---|---|---|---|---|---|
| Gilead Sciences s.r.o. | Praha | 93 636 466,56 | 83 603 988,00 | CZK |